Conference Proceedings
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis
Chris Burns, Terrie-Anne Cock, Anthony Bishop, Nicole Kruger, Sarah McCormack, Sumitra Ananda, Marion Harris, Warren Lance Joubert, Jin Won Kim, Choong-kun Lee, Woo Jin Lee, Larissa Rachel Lipton, Adnan Nagrial, Do-Youn Oh, Joon Oh Park, Nick Pavlakis, Jason Lickliter
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2024
Abstract
e16337 Background: Narmafotinib (AMP945) is a highly potent and selective, orally bioavailable inhibitor of Focal Adhesion Kinase (FAK). FAK is a non-receptor tyrosine kinase over-expressed in pancreatic cancer, where it contributes to cell survival, proliferation, migration and chemoresistance and thus plays a key role in tumor growth, FAK also contributes to multiple mechanisms underlying fibrosis and immunosuppression in the tumor microenvironment. Narmafotinib has successfully completed a Phase 1 study in healthy volunteers where the drug was safe and well tolerated with pharmacokinetics consistent with once-a-day dosing. A Phase 1b/2a trial of narmafotinib, in combination with gemcitab..
View full abstract